增强肝纤维化评分可用于预测非酒精性脂肪性肝炎合并代偿性肝硬化患者的肝脏相关事件
该研究评估了增强肝纤维化(ELF)评分在代偿性非酒精性脂肪性肝炎(NASH)肝硬化患者中预测短期肝脏相关结局的预后价值。ELF评分基于透明质酸、TIMP-1和PIIINP等循环标志物,可较可靠地识别晚期纤维化患者,但其在代偿性肝硬化中的预后作用尚不明确。
要点
- ELF评分由透明质酸、TIMP-1和PIIINP组成,可较可靠识别晚期纤维化。
- 代偿性NASH肝硬化患者需要无创工具识别肝失代偿高风险者。
- 该研究评估ELF评分预测代偿性NASH肝硬化短期肝脏相关结局的价值。
核心结论
- 该研究评估了ELF评分对代偿性NASH肝硬化患者短期肝脏相关结局的预后意义。
研究设计与样本
- 研究设计与样本量原文未报告。
主要发现
- 原文未报告具体研究结果。
关键数值与推荐
- ELF评分由透明质酸、TIMP-1和PIIINP组成。
- ELF评分可较可靠地识别NAFLD晚期纤维化患者。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There is a growing need for a noninvasive tool to identify patients at higher risk of hepatic decompensation among individuals with compensated nonalcoholic steatohepatitis (NASH) cirrhosis.1 Hepatic venous pressure gradient (HVPG) has value in risk stratification2 and prediction of mortality among cirrhotics3 but has limitations of being invasive, costly, and a requirement for expertise.4 The Enhanced Liver Fibrosis (ELF) score is based on circulating markers of hepatic matrix turnover and consists of hyaluronic acid, TIMP-1 (tissue inhibitor of metalloproteinases-1), and PIIINP (propeptide of type III collagen). It identifies nonalcoholic fatty liver disease (NAFLD) patients with advanced fibrosis quite reliably.5,6 However, its utility as a prognostic biomarker among individuals with compensated cirrhosis due to NASH is unclear. This study evaluated the prognostic significance of the ELF score for predicting short-term liver-related outcomes among patients with compensated NASH cirrhosis.
引用
- Are VS, Vuppalanchi R, Vilar-Gomez E, et al. Enhanced Liver Fibrosis Score Can Be Used to Predict Liver-Related Events in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis. Clin Gastroenterol Hepatol. 2020. PMID: 32629127. doi:10.1016/j.cgh.2020.06.070
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。